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INTRA-ARTERIAL CHEMOTHERAPY OF MALIGNANT DISEASES* 
R. W. T A I i F.Y. M.D. . V. K. VAITKEVICIUS, M.D . . 
M . J. BRENN.AN, M.D. , AND J. E. K E L L Y , M . D . * * 
During the past two decades the interest in the application ot chemicals to Ihe 
palieni with inoperable, radiation-resistant, malignant disease has markedly increased. 
Many compounds have been evaluated and those which have show n etlicacy have been 
limited in usefulness by their general swstemic loxicitv. Even though ihe tiuesl lor 
new, relatively non-toxic chemicals is progressing at a rapid rate, there is no evidence 
of which we are aware thai such an agent is out of Ihe test lube. 
However, by the administration of these agents intra-arterially their sysiemic toxi-
Li may be decreased. .Several meihods have been employed and, for sake of simpliciiv. 
wc have divided ihese into Ihe following ihree categories: ( 1 ) acute infusion, (2) acule 
perfusion, and (?•) chronic infusion with anlidole. The technique ot acule infusion 
was first described by Klopp' and results will not be discussed here hut in a subse-
quinl publication. 
RESULTS 
The acule perfusion lechnique as first described by Creech and co-workers' has 
been most applicable in tumors localized in an extremil\ in which ampulalion or 
oihci sur '^ical lechnique could not be employcil. However, perfusion of Ihe pelvis, 
lung .^ brain, and olher vascular isolalable organs are under evaluaiion. in a recent 
Perlusion Conlerence held al Tulane University in New Orleans, Ihe lesulls of man\ 
invcsiigalors were presented and, for a comprehensive survey, the reader is referred 
to the publication' of this conference. 
In perfusion of an extremity the vascular supply of the area is isolated surgicallv 
I with cannulizaiion of ihe major arlery and vein and lourniquel applied proximal lo 
ihcsi.'. Ihe chemotherapeutic agent, usually an alkylating agent, is ailminislered by a 
Uigmamolor pump extracorporeal system with bubble oxygenator. The drug employed 
in all of our cases except Iwo has been nitrogen mustard al a dose of 0.6 lo 1.0 mg./kg. 
hVe have found that, by careful monitoring of the perfusion system and ihe palienl's 
hlooJ from a disianl sight with chromale labeled red cells, as well as keeping ihe 
perfusion system pressure (Austen and co-workers)' below the patient's average blood 
pressure, systemic toxicity may be kept to a minimum. 
The seven patients undergoing such procedure are listed in Table I . Two of IIKSC 
Ipaticnts (#3 and 7) can be classified as prophylaclic perfusions; Ihe rationale for 
buch prophvlaclic perfusion has been convincingly pul forth by Slehlin.' Palients #2 
land #5 had worthw hile responses. Patient #5 is a 31-year-old, w hite female w iih 
recurrent melanoma (Fig. I) in righl epilrochlear node and righl axillary nodes. 
|Axillar\ node dissection followed bv perfusion with nitrogen mustard at 1.0 mg. kg. 
jr^ulied in 7 cm. decrease in circumference of arm. There has been no evidence of 
regrowih of the tumor five months after the perfusion. 
I 'Presenlcd at Regional Meeting, American College of I'hysicians. Flint, Mich., December y, i'>W). 
l^partmcnt of Medicine. Division of Oncology. 
4. H / 
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TABLE I 
r iRFUSION RESULTS WITH ALKYLATING ACiENTS 
Patient Diagnosis 
I M.L. C ,1 Bladder 
2. R.W. 
V K.S. 
Ewings 
Sarcoma 
Mclanoni.i 
Squamous 
cell ca. 
Melanoma 
Melanoma 
Pcrlusitm 
Site 
Drug and 
Dose Toxicity 
Olher 
RX Results 
Pelvis TESPA 
60 mg. 
W lU ^ 5 0 0 
— Subj., 4 wk 
I eft leg H N , . 0.6 
mg./kg. 
WBC- 2.(K)0 Radiation 
6,000 r 
No recur in 
9 months 
Left leg H N , . 0.8 
mg. kg. 
N & V Radical 
groin 
dissection 
No recur in 
9 months 
Right leg TESPA 
60 mg. 
Radical 
groin 
dissection 
No effect 
Right arm H N , . 1.0 
mg./kg. 
N & \- Axi l lary 
dissection 
Obj. rem. 
.*> months 
Right leg H N , . 0.8 
mg./kg. 
Sciatic 
nerve 
paresthesias 
Inguinal 
dissection 
No effect 
Right leg H N , . 0.8 
mg./kg. 
\ esicular 
dermatitis. 
Peroneal 
nerve palsy 
Inguinal 
dissection 
Prophylac. 
only — no 
recur in 
5 months 
9 -n-60 
Fiuurc I 
Patient #5, M. L., shov^ ing site of cpiiiochleai metastases of a recurrent melanoma. The circu, 
ference of upper arm on September 1.^  1960, was 35 cm. and on October 5, I960, it measured 27 err. I 
Patient #2 is a 16-year-old boy with Ewing's sarcoma of the left femur (Fig. 2i 
Local acute perfusion with nitrogen mustard at 0.6 mg./kg. resulted in decrease in pain 
and swelling of leg. This was followed by 6,000 r delivered by a cobalt teletherap) 
unit. There has been no recurrence of disease eleven months later. It is impossible j 
to sav whether such combined therapy has been or will be any more efficacious thani 
radiation therapy alone, but it is planned to treat additional patients in such a manrK 
if the opportunity arises. 
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Figure 2 
Rocmgenograms of left femur in patient #2. R. W.. reveal typical "onion peel" appearance of lefi 
femur. Large defect is the biopsy site. There has been complete disappearance of the "onion skin ' 
appe.trance in the film of 10/5/60 and, expect for thickening of cortex, the bone appeals normal. 
This film was taken 8 months after nitrogen mustard perfusion and radiation therapy. 
The third technique being discussed, chionic arterial infusion of antimetabolite 
with systemic metabolite therapy and the rationale for such, was recently described 
by Sullivan.* In this technique, an antimetabolite such as amethopterin is adminis-
tered via a constant arterial infusion to a localized area by a Barron pump.' Simul-
taneously, the patient is given relatively large doses of the normal metabolite such as 
folinic acid to prevent or delay systemic toxicity. Amethopterin is administered in a 
dose of 50 mg./day via arterial infusion for at least four days and folinic acid is 
given in intermittent daily doses of 9-36 mg. intramuscularly. Fifteen patients have 
been treated by this technique and are presented in Tables 11, III, and IV according 
to the area infused. 
I TABLE II ^ 
ARTERIAL INFUSION WITH AMETHOPTERIN 
A. Pelvic Infusion via Hypogastric Arteries 
Patient Diagnosis Total Dose 
(Mi l l igrams) 
Respo 
Subj, 
nse 
Obj. 
Minimal 
WBC 
Other 
Toxicity 
I G.S. Ca. Cervix 310 mg. t | t 5 mo. t 2 mo. 950 Diarrhea, 
stomatitis 
^ M.K. Ca. Cervix 200 mg. t 1 mo tv 1 mo. 700 Staph-eniero 
colitis 
^ K.C. (a) 
(b) 
Ca. Colon 
Ca. Colon 
175 mg. 
125 mg. 
0 
0 
* 
T M50 20(K) 
Diarrhea 
Diarrhea 
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1 ABLE III 
ARTERIAL INFUSION WITH AMETHOPTERIN 
B. Via Internal Carotid 
Patient Diagnosis Total Dose 
(Mi l l ig iams) 
Response 
Subj. Obj . 
Minimal 
WBC 
Other 
Toxicity 
4. H.R. Glioblastoma 350 mg. 0 t 3500 — 
5. R.M. Cilii>blastoma 525 mg. V 1 mo. t t 1 mo. 1450 Diarrhe;i 
6 P D. (a) 
(b ) 
Vleningiosarc. 
Meningiosarc. 
100 mg. 
250 mg. — — 
6000 
750 Dead on 
7th post-
inf. day 
7 H.G. Astrocytoma 250 mg. 8200 Death 1 
day post 
infusion 
TABLE IV 
A R T E R I A L I N F U S I O N W I T H 
C. Via External Carotid 
\ M E T H O P T L R I \ 
Patient Diagnosis Total Dose 
(Mi l l igrams) 
Response 
Subj. Obi. 
Vlinimal 
WBC 
Other 
Toxicity 
8. D.R, (a) 
( b ) 
Ca. Floor of 
Mouth 
Ca. Floor of 
Mouth 
490 mg. 
412.5 mg. 
i- i^t 1 mo. t t t I mo. 
ttt 
4200 
1450 
Stomatitis 
Slomalilis 
9. H H. Ca. Tonsil 350 mg. 50 Dealh- l.euko 
penia. acute 
pulm. edemi 
10. L A. Ca. Pharynx 350 mg. t — 2600 Stomatitis A 
severe anx'y 
1! R.K. Ca. Tongue 350 mg. t t 3 wks 4800 C V A ' 
i : SAL (a) 
( b l 
Ca. Tongue 
Ca, Tongue 
335 mg 
290 mg. 
t t 3 wks 
j t 7 wks 
t 3 wks 
t t 7 wks 
3100 
1250 
Stomatitis, 
diarrhea, & 
hronchopneu 
13. J K. (a) 
(b ) 
(c) 
Osteogenic 
Sarcoma 
Zygoma. 
300 mg. 
300 mg. 
200 mg. 
tt 
t M 5 wks 
t 
t 
t t 4 wks 
3800 
2800 
4350 
Stomatitis 
Stomatitis 
14. J.E. Melanoma 200 mg. — — 42(K) Inf. D / C d * 
patient req. 
15. V.D. ( 1. Breast. 240 mg. t t 3300 Stomatilis 
s alp mefast. Hcmoirh ige 
Three hypogastric artery infusions for pelvic carcinoma (Table III), resulted 
in production of significant subjective and objective improvement in one paticni 
with carcinoma of the cervix, definite but limited benefit in another patient wit 
carcinoma of the cervix, and no help in a patient with carcinoma of the rectum. 
Four patients with various brain tumors were infused via the internal caroti»i 
artery as shcTwn in Table IV. Only one patient (H.R.) obtained objective benefit witlij 
decrease of intracranial pressure to normal and disappearance of pain, but becau^ i 
Intra-Arterial Chemotherapy of Mali{>nant Diseases 
ic-cxisimg brain damage, this response was considered to be of limited value. 
Fight patients have been infused via the external carotid artery and objective 
subjective benefits have been noted in six, but of short duration in all (Table I V ) . 
Sullivan* reported significant prolonged regressions in three of eighteen patients 
I ed similarly. Prolonged regressions were not noted in our series, but WiMihsshile 
pjil.ation was obtained in four patients. Ihe most gratifying result was obtained in 
padcnt #8, a 50-year-old man with recurrent radiation-resistant carcinoma of fhe 
floc of the mouth with direct extension through the mandible, in whom the infusion 
carried out on two occasions. Afler both infusions there was dramatic diminution 
of 'le tumor mass (Fig. 3), but afler the first infusion there was rapid regrowth of the 
I T 
12-9-59 2-2 60 
Figure 3 
Patient #8. D. R. (Table I I I ) . \Mih carcinoma of floor of the mouth with direct extension through 
the nmndiblc. Photograph prior lo Amethopterin infusion and appearance of lesion 4 d.i\s atiei 
completion of second infusion. 
« 
tumor. Because of the rapid growth of the tumor after the first infusion and the 
obvious fact that not all of the lumor had responded alter the second infusion, a radical 
excision of the anterior half of the mandible and tongue was performed. The patho-
logic specimen did nol reveal any recognizable viable malignant cells in the marginal 
'yniph nodes and edges of the excised specimen. Ihere has been no recurrence in 
eleven months and the paiient is now undergoing plastic reconstruction of the face, 
t^ is impossible lo say whether or nol such a surgical procedure would have been 
possible withoul chemotherapy, however, this palieni had been considered inoperable 
several examiners. 
TOXICITY 
Toxicity associaled with alkylating agent perfusion has been summarized recentl\ 
)^ Reemstra.' Gastrointestinal reactions, leukopenia, nerve injuries, skin erMhema, 
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and skin ulceration were ihe most common complications noted in a series of 231 
perfusions. All of these were noted in our small series of seven patienls. The most I 
marked leukopenia was noted in palieni #1, in whom pelvic perfusion was undertaken,' 
and had an approximate 70^ leak as calculated by chromiumjs-tagged red cells 
The toxicities are summarized in Table I. Our series is too small to give any true 
incidence of these complications. 
The major toxicity associated with the chronic infusion of amethopterin was that 
of bone marrow depression with leukopenia and thrombocytopenia. Ulceration of the| 
buccal mucosa in external carotid infusions and of diarrhea in hypogastric infusions| 
were a problem in about one-half of each group. There were two deaths in association 
with severe leukopenia. 
The dose relationship of folinic acid lo leukopenia in the amethopterin treated 
patient is of great importance and leukopenic responses in relation to three dose levels! 
of folinic acid is demonstraled in Fig. 4, 5, and 6. The maximal leukopenia in patients 
receiving less than 35 milligrams of folinic acid a day occurred by the 8th day, in thc| 
majority of patients. Recovery to normal levels in all of these palients was about thej 
same. Patienls receiving 36 or more milligrams a day did not drop to as low a ICNCI 
and recovered more rapidly, however, the differences were not great. Two fatal 
Aiy^ETHOPTERIN ARTERIAL INFUSIOhi 
FOLINIC ACID DOSE > 20mq/d 
Amet -•• Folinic Acid 
Folinic Add Only 
tc.s 
L A 
•» 1 ' I ' I ' 1 ' 1 ' 1 ' r 
8 10 12 14 16 18 20 
DAYS 
Figure 4 
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AMETHOPTERIN ARTERIAL 
INFUSION 
FOLINIC ACID DOSE 2 0 - 3 5 mq/d 
Amet • Folinic Acid 
Folmic Acid Only 
DAYS 
Figure 5 
AMETHOPTERIN ARTERIAL 
INFUSION-LEUCOCYTES 
FOLINIC ACID DOSE 36-tmq/d 
Amet • Folinic Acid 
1"J'-\FOI inic Acid Only 
p S Ml 
DAYS 
Figure 6 
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leukopenic reactions occurred and. in one patient, P. D., in whom the amethopterin 
liisconiinucd when Ihe peripheral while biood count was still 8,400. Partly 
because of this, we now rely heavily on cytological changes in the bone marro v 
vAhich demonstrate progressive evidence of megaloblastic changes in the erythroid 
.r'.s. increase in granulocytic-ervthroid ratio, and disappearance of immature granu-
locytes. 
In I'ig. 7 (a-h.) we see aUpical erythroid and granulocytic elements developing 
in nalient #4 (H.R.), receiving 50 milligrams amethopterin daily via the internal 
e;iroiid arterv and milligrams of folinic acid intramuscularly daily. The first 
i\pie.il nieLi.ilol-'l.isiic cell suggesting a thymine deficiency' is seen at 28 hours. Approxi-
matclv 48 hours is iei|uirei.i lor disappearance of the major abnormalities. It is 
-nv s^ etl from this that a greater dose than 36 milligrams of folinic acid is necessary 
Figure 7a 
C oiiiiol \ptviiiioii >ho»inp normoblasls 
. i i i i l i n \ i - l o . . \ l i ' N . 
- 7b 
t'icmcnlN from palieni II R. 
> 
Figure 7b 
•J hours — e.ssenli.illv normal nornioblasi<i 
an.i .-.o: 
Figure 7c 
I ft hours — large normoblasls, with loosening 
of nuclear ihromalin, and glani melamyelocvtes. 
Figure 7d 
2S hours — lypical mcgaloblasl. double 
nuclc.iieil normoblast. 
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.^ 6 hours 
Figure 7e 
- Iripolar miloiic ligiirc. 
Figure 7f 
.JS hoiiis — typical mcgaloblasl, spaiscncss 
of myelocytes. 
Figure 7g 
24 hours after discontinuance of .Amethopterin 
— mcgaloblasl with increasing condensation of 
nuclear chromatin. 
Figure 7h 
48 hours afler co.r.plelion — macrocytic 
normobl isi and hyperse^nienled granulocytes. 
S U M M A R Y 
Intra-arterial administration of alleviating agents and antimetabolites have become 
more practicable with the development of newer lechnic|ues and, in occasional instances, 
have produced elTectivc palliative results. However, the toxicity Irom anv o\ our 
currently available chemotherapeutic agents is still a significant hazard even Irom 
•Tterial administration techniques. 
Perfusion of an isolated vascular area appears to be beneficial primarily in 
'"mors in an extremily, though development of techniques lor perfusion ol olher 
•Teas are in progress. However, this is primarily a surgical problem and we depeml 
<"> our surgical colleagues for developments in this area. 
Ihe administration of amethopterin intra-arleriallv lo 15 patients while simul-
•nci'iis|\ ,idniinistering lolinie .leid li..s been ol deliiiiie but Imnicil value in i\ ol \2 
P*lients with carcinoma in the head or neck region, and I of .3 palienis with pelvic 
•"ircinoma. No definite benefit was noted in patients with brain tumors. The toxicity 
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ot such therapy is significant. Amethopterin infusion should be undertaken only in 
patients willing to accept a definite hazard. It must be stressed, however, that in many 
patients there is no other therapy available. If procedures such as those described here 
are uncleri.iken with caution, some patients will obtain a degree of palliation not pre-
viously available to them. 
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